Entries by Thomas Gabrielczyk

Macrocycles: big is the new beautiful

In the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators ­continually strive to develop therapies that are both highly ­selective and clinically effective, while addressing targets ­previously deemed “undruggable”. In recent years, macrocycles – a class of large, ring-shaped molecules – have emerged as a compelling solution at the crossroads between ­traditional small molecules and large biologics, offering a blend of high specificity, rich chemical diversity and promising pharma­cological profiles.

Swiss Windward Bio adds US$165m to its Chinese pipeline

Basel-based Windward Bio did it again and has raised another three-digit millions – $165 million to be exact – to advance a pipeline of long-acting immunology therapies—much of it sourced through in-licensing deals with Chinese partners. Its lead candidate, WIN378, is moving into Phase III, with first clinical readouts expected from 2026.

Inside Servier’s new €200M venture fund

With the launch of Servier Ventures announced in January and a €200 million commitment to biotech investment, Servier is stepping up its engagement in early-stage ­innovation in oncology and neurology. European Biotechnology Magazine spoke with ­Alexis Vandier, Global Head of Servier Ventures, about the fund’s strategy, investment ­focus, and ­Europe’s role in the global biotech ecosystem.

Astorg spins off Thermo Fisher’s microbiology arm

Pan-European private‑equity firm Astorg has agreed to acquire Thermo Fisher Scientific’s global microbiology business for about US$1.08bn, carving it out into a standalone platform focused on antimicrobial susceptibility testing and microbiology diagnostics. The investment is being made through Astorg VIII, the firm’s latest flagship buy‑out fund.